GlassScriptPhysician profile
Mark A Martindale
NPI 1205911849
$2,723.43
in general payments reported to CMS, 2019-2025
34 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $403 · 2021: $221 · 2022: $443 · 2023: $584 · 2024: $247 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $324.17 | 2019-2023 | Farxiga |
| Abbvie INC. | $254.20 | 2022-2024 | |
| Abbott Laboratories | $229.20 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Allergan, INC. | $226.51 | 2019-2020 | |
| Dexcom, INC. | $210.36 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $142.78 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $118.78 | 2020-2022 | |
| Medtronic Minimed, INC. | $116.27 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $89.15 | 2021-2025 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $86.75 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $80.34 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $77.66 | 2023-2025 | Repatha, Repatha, Otezla |
| Sequel Med Tech, LLC | $66.79 | 2025 | Twiist |
| Medtronic, INC. | $60.10 | 2022-2025 | Minimed 780g |
| Idorsia Pharmaceuticals US INC | $59.24 | 2022-2024 | Quviviq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $58.89 | 2021-2023 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.87 | 2024-2025 | Caplyta |
| Pfizer INC. | $48.59 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $41.16 | 2021-2023 | Austedo, Ajovy |
| Tandem Diabetes Care, INC. | $34.99 | 2019 | |
| Phathom Pharmaceuticals, INC. | $33.29 | 2024-2025 | Voquezna |
| Supernus Pharmaceuticals, INC. | $32.56 | 2023-2024 | Qelbree, Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.46 | 2021-2023 | Jardiance |
| Corium, LLC | $29.63 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $29.57 | 2025 | |
| Insulet Corporation | $28.30 | 2025 | Omnipod |
| Vanda Pharmaceuticals INC. | $25.54 | 2025 | Fanapt |
| Seqirus USA INC | $23.16 | 2025 | Flucelvax |
| Otsuka America Pharmaceutical, INC. | $20.53 | 2022 | |
| Lundbeck LLC | $20.28 | 2025 | Vyepti |
| Solventum Corporation | $18.48 | 2025 | V.A.C. Veraflo, V.A.C.Ulta, Activ.A.C. |
| Grifols USA, LLC | $15.65 | 2023 | Prolastin-C Liquid |
| E.R. Squibb & Sons, L.L.C. | $14.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Martindale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.